SRF231, a fully humanized anti-CD47 antibody, has demonstrated an ability to increase phagocytosis in AML cell lines, including the p53-null HL60 cell line, as well as in primary bone marrow samples from patients with AML [96]. The gene discussed is CD47; the disease is acute myeloid leukemia.